caa a22 4500 477107745 CHVBK 20180405111600.0 cr unu---uuuuu 170330e19961001xx s 000 0 eng 10.1007/BF01809745 doi (NATIONALLICENCE)springer-10.1007/BF01809745 Nimodipine in traumatic subarachnoid haemorrhage: A re-analysis of the HIT I and HIT II trials [Elektronische Daten] [G. Murray, G. Teasdale, H. Schmilz] Summary: Two large randomised controlled trials have been performed to study the effect of the calcium antagonist nimodipine on the outcome of severe head injury, HIT I [1] amd HIT II [4]. Both trials showed a modest and statistically non-significant increase in the proportion of favourable outcomes in patients treated with nimodipine. A subgroup analysis of the HIT II trial [4, 5] suggested, however, that there could be a substantial protective effect of nimodipine in patients with traumatic subarachnoid haemorrhage (SAH). This report provides a re-analysis of the HIT I data to see whether it provides confirmatory evidence of the subgroup effect observed in HIT II. This involved performing a central review of the CT scans for the HIT I patients, to identify those individuals with evidence of traumatic SAH. The sample size was small, but the HIT I data gave no support to the hypothesis that nimodipine is protective in the traumatic SAH subgroup, where 69% of patients had a poor outcome on placebo and 74% of patients had a poor outcome on nimodipine. The data do not exclude the possibility of a clinically relevant beneficial effect of nimodipine in the traumatic SAH subgroup, but further data are required to provide a definitive answer. In addition, we present a pooled analysis of the data from the two trials, which suggests that the overall benefit of treating unselected head injured patients with nimodipine is unlikely to be clinically relevant. Springer-Verlag, 1996 Nimodipine nationallicence overview nationallicence severe head injury nationallicence sub-group analysis nationallicence traumatic subarachnoid haemorrhage nationallicence Murray G. Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow aut Teasdale G. Department of Neurosurgery, University of Glasgow, Glasgow, UK aut Schmilz H. Biometrics Department, Bayer AG., Wuppertal, Federal Republic of Germany aut Acta Neurochirurgica Springer-Verlag 138/10(1996-10-01), 1163-1167 0001-6268 138:10<1163 1996 138 701 https://doi.org/10.1007/BF01809745 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01809745 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Murray G. Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow aut NATIONALLICENCE 700 1- Teasdale G. Department of Neurosurgery, University of Glasgow, Glasgow, UK aut NATIONALLICENCE 700 1- Schmilz H. Biometrics Department, Bayer AG., Wuppertal, Federal Republic of Germany aut NATIONALLICENCE 773 0- Acta Neurochirurgica Springer-Verlag 138/10(1996-10-01), 1163-1167 0001-6268 138:10<1163 1996 138 701 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer